### Pulmonary: Cystic Fibrosis

<table>
<thead>
<tr>
<th>Short Name</th>
<th>Comments</th>
<th>Type</th>
<th>Investigator</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disease site specific</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| CF Registry | Cystic Fibrosis Registry | Registry | Dr. Susan Millard | Tom Symington  
thomas.symington@spectrumhealth.org  
616.391.9366 |
| VX20-121-102 | **A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)** | Treatment | Dr. Courtney     | Tom Symington  
thomas.symington@spectrumhealth.org  
616.391.9366 |

This study is an ongoing data collection effort sponsored by the Cystic Fibrosis Foundation, known as the Patient Registry. The goal of the Patient Registry is to collect data to better understand the illness and ultimately improve the care and survival of those with CF. The Patient Registry was established in 1966 as a means to monitor important trends in the CF population and to improve understanding, treatment, and survival.